Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Claudia Haferlach Michael Lauseker Alice Fabarius Markus Pfirrmann Susanne Schnittger Hermann Einsele Gerhard Ehninger Michael Pfreundschuh Andreas Hochhaus |
| Publication date | December 2, 2013 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |